The Financialization of Disruptive Technology
The Agile Manager
SEPTEMBER 30, 2019
A recent FT Lex article on biotech investing drives the point home: "A 20-year study found only one-fifth of exits were profitable. Cheap capital makes it easy for anybody to enter the innovation game. Deep pocketed investors make it expensive to stay in the innovation game. Investment yields are highly concentrated.
Let's personalize your content